Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
179
resultados
Última actualización
02/11/2026 [08:44:00]
Resultados 50 a 75 de 179
Resumen de: US20260305986A1
Methods and apparatus for providing data processing and control for use in a medical communication system are provided. Such methods and apparatus may include determining a glucose value in a bodily fluid based on an estimated glucose temperature related signal and the glucose related signal in the bodily fluid, wherein the glucose temperature related signal may be estimated based on the temperature of the skin or the ambient temperature.
Resumen de: US20260305987A1
0000 The present disclosure relates to a continuous blood glucose measurement device configured to prevent, in a state where a body attachment unit is inserted in and attached to a human body, an incision portion made by a guide needle from being formed to surround at least a part of a sensing area formed at a sensing member, whereby an incision portion is not formed around the sensing area so as to prevent the incision portion from causing a drop in a blood glucose measurement value and thus enable detection of an accurate blood glucose measurement value from the early stage of operation. Further, the guide needle has a shape not surrounding at least a part of the sensing area, so as to prevent, even without an additional device, the guide needle from forming an incision portion around the sensing area in a human body and thus enhance, by a simple structure, the accuracy of blood glucose measurement.
Resumen de: US20260305988A1
0000 A system for displaying blood glucose information includes a blood glucose monitoring device configured to monitor blood glucose levels of a user, and a display. The system may also include one or more processors, and a non-transitory computer-readable medium containing instructions that, when executed by the one or more processors, cause the system to perform operations. The operations may include obtaining the blood glucose levels from the blood glucose monitoring device, where the blood glucose levels include at least a current blood glucose level and a historic blood glucose level. The operations may also include presenting the current blood glucose level at a first location on the display based on a first scale, and presenting the historic blood glucose level at a second location on the display based on a second scale different from the first scale.
Resumen de: US20260306741A1
In an aspect, the present disclosure provides an insulin delivery device configured to be positioned on a body of a subject via a single puncture site in said body of said subject, wherein said insulin delivery device is configured to deliver an insulin or insulin analog formulation to said subject via said single puncture site, wherein said insulin delivery device comprises a sensor configured to measure a glucose concentration in said body of said subject via said single puncture site, and wherein said delivering and said measuring are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning, while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.
Resumen de: US20260311863A1
0000 According to an embodiment of the present disclosure, there is provided a method for assisting glycemic control of a subject using a computer system, the method including acquiring a self-set goal of the subject; acquiring GA values of the subject; generating a GA value trend using a plurality of the GA values; outputting the GA value trend to the subject; and outputting the self-set goal of the subject to the subject.
Resumen de: US20260311579A1
A modular patient monitor provides a multipurpose, scalable solution for various patient monitoring applications. In an embodiment, a modular patient monitor utilizes multiple wavelength optical sensor and/or acoustic sensor technologies to provide blood constituent monitoring and acoustic respiration monitoring (ARM) at its core, including pulse oximetry parameters and additional blood parameter measurements such as carboxyhemoglobin (HbCO) and methemoglobin (HbMet). Expansion modules provide blood pressure BP, blood glucose, ECG, CO2, depth of sedation and cerebral oximetry to name a few. Aspects of the present disclosure also include a transport dock for providing enhanced portability and functionally to handheld monitors. In an embodiment, the transport dock provides one or more docking interfaces for placing monitoring components in communication with other monitoring components. In an embodiment, the transport dock attaches to the modular patient monitor.
Resumen de: US20260306030A1
0000 Embodiments relate to systems and methods for informing, determining, or controlling insulin dosage. The method involves generating plural disturbance profiles, each disturbance profile being a data representation based on historical patient data pertaining to a deviation from a threshold blood glucose level. The method involves receiving current patient data. The method involves applying a predictive model so that current patient data is compared to a disturbance profile and a probability analysis is used to assess the likelihood of a disturbance profile being an anticipated disturbance profile, the anticipated disturbance profile being a disturbance profile that is determined to match with the current patient data based on the probability analysis. The method involves determining an insulin dose amount based on the anticipated disturbance profile. The method involves outputting a signal representative of the insulin dose amount to a device configured for monitoring, influencing, and/or administering insulin levels in the patient.
Resumen de: WO2026212984A1
In some embodiments, a system for optimizing insulin bolus timing for a patient includes a continuous glucose monitoring (CGM) sensor worn by the patient, where the CGM sensor is operable to generate time-series glucose measurements. The system also includes one or more memories having executable instructions and one or more processors in data communication with the one or more memories. The one or more processors are configured to execute the executable instructions to perform one or more operations that include receiving the time-series glucose measurements and automatically determining a current need for an insulin bolus based on an evaluation of the time-series glucose measurements over a current period, where the current need corresponds to an affirmative determination or a negative determination. The one or more operations further include conditionally inviting the patient to initiate an application flow for automatically determining insulin bolus advice based on the current need.
Resumen de: WO2026211868A1
The present invention relates to an agent for improving the characteristics of a peptide and a method for improving the characteristics of a peptide. The present invention also relates to an α-glucosidase having the activity of binding D-glucose to an N-protective amino acid. The present invention also relates to a method for producing an amino acid glycoside. TThe present invention also relates to a method for producing an amino acid glycoside. The agent and method of the present invention utilize a single amino acid glycoside, or a dipeptide or tripeptide containing one or more amino acid glycosides. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 11; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 11; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 11. The α-glucosidase of the present invention has: (1) an amino acid sequence of SEQ ID NO: 14; (2) an amino acid sequence in which one or more amino acids are deleted, substituted, inserted, or added in SEQ ID NO: 14; or (3) an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 14. A method for producing amino acid glycosides of the present invention includes a step for generating amino acid glycosides by reacting a carbohydrate hydrolase that acts on amino acids or amino acid derivatives and binds D-glucose with a par
Resumen de: US20260308530A1
0000 Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/Ki-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
Resumen de: WO2026212052A1
A method and an electronic device for monitoring a user's health status using a generative artificial intelligence model are provided. The method includes: acquiring user condition information including at least one of blood glucose, blood pressure, heart rate, ketone concentration, cholesterol, lactate, or insulin from an external electronic device; acquiring history information related to the user condition information; determining the user's health status by using the generative artificial intelligence model based on the user condition information and the history information; determining information or a service for the user based on the user's health status; and providing the information or the service.
Resumen de: US20260306804A1
Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspensions of one or more ingredients. In embodiments of the present invention, amounts of the formulation and/or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.
Resumen de: US20260308529A1
0000 Disclosed herein are compositions and methods for generating compositions comprising cell-based therapeutics useful for treating pancreatic disorders, including Type 1 diabetes.
Resumen de: WO2026211288A1
This liquid material for encapsulation at the time of intrauterine embryo transfer according to the present invention contains human serum albumin, glucose, alanyl-L-glutamine, hyaluronic acid, and two or more fatty acids. At least one unsaturated fatty acid selected from the group consisting of arachidonic acid, linoleic acid, linolenic acid, oleic acid, and palmitoleic acid and at least one saturated fatty acid selected from the group consisting of myristic acid, palmitic acid, and stearic acid are used as the two or more fatty acids.
Resumen de: WO2026213025A1
The present examples relate generally to apparatuses, systems, and methods for force reduction for medical device sensors. The apparatuses, systems, and methods may be directed to force reduction for a transcutaneous analyte sensor for insertion into a host. The medical device may comprise an on-skin wearable medical device. The on-skin wearable medical device may include a transcutaneous glucose sensor.
Resumen de: US20260305975A1
0000 A non-invasive glycemic monitoring system uses a breath-sensing device to acquire repeated breath sessions from a user and to generate volatile organic compound information together with sample-quality and environmental information. A computing system receives a lab-derived A1C baseline for the user and uses the baseline with the breath-derived information to initialize and update a personalized model. Accepted breath sessions are stored in a rolling history and used to generate a projected A1C trend and a daily progress score or zone output representative of the user’s glycemic trajectory. In some embodiments, humidity, temperature, and sample-quality information are used to normalize breath-session data, and optional external inputs including finger-stick data, continuous glucose monitor data, or other external data are fused with the breath-derived information to refine personalization, anomaly handling, reporting, and confirmatory prompts.
Resumen de: WO2026212054A1
A method and smart glass for providing personalized information for health management are disclosed. The method comprises: acquiring an image through a camera; identifying at least one object included in the image acquired through the camera; acquiring sensing data related to blood glucose from an external electronic device; calculating at least one of a current blood glucose value and a predicted future blood glucose value based on the identified object and the sensing data; and displaying at least one of the current blood glucose value and the predicted future blood glucose value through a display.
Resumen de: US20260309669A1
Creatinine levels may be monitored as a measure of kidney function. Conventionally, blood and/or urine tests are used for this purpose. Analyte sensors capable of monitoring creatinine in vivo may comprise: a sensor tail comprising at least a first working electrode, a creatinine-responsive active area disposed upon a surface of the first working electrode, a first membrane that is permeable to creatinine and overcoats the creatinine-responsive active area, and an oxygen scavenger located upon the sensor tail in proximity to the creatinine-responsive active area. The creatinine-responsive active area comprises a first electron transfer agent, a first polymer, and an enzyme system comprising multiple enzymes, particularly creatinine amidohydrolase, creatine amidinohydrolase, and sarcosine oxidase, that are capable of acting in concert to facilitate detection of creatinine. An oxidase enzyme may serve as the oxygen scavenger, particularly glucose oxidase when detecting creatinine in fluids also containing glucose.
Resumen de: WO2025117799A1
Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.
Resumen de: EP4817520A2
An example method for initializing a glucose sensor includes executing an initialization sequence for the glucose sensor, wherein the initialization sequence is based on one or more of parameters related to manufacturing the glucose sensor or environmental conditions of the glucose sensor that are present in vivo, and reporting glucose levels in a patient after the initialization sequence.
Resumen de: WO2025117512A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: US20250170330A1
0000 Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: MX2025002639A
The present invention describes a method for detecting chronic kidney disease (ERC) in samples from subjects with type 2 diabetes (DT2) by metabolic analysis. This method is based on two approaches: a panel of metabolite/creatinine (met/Cr) ratios and a statistical model developed from the spectral profile obtained by hydrogen nuclear magnetic resonance (1H NMR). The method was tested in a cohort of samples from subjects with type 2 diabetes in order to identify renal damage in early stages. The directed metabolomica allows to evaluate the metabolite/creatinine ratio, while the non-targeted metabolomica, based on the 1H NMR spectrum, facilitates initial ERC prediction by statistical analysis and identification of the most affected metabolic pathways. This invention makes it possible to differentiate stadiums from chronic kidney disease and even detect their presence in subjects without obvious symptoms. Its efficacy is supported with a sensitivity of 1,000 and a specificity of 0.895 in the control group, demonstrating its high yield in early identification of the disease. This advancement offers an innovative tool for improving the detection and treatment of CKD in diabetic subjects.
Resumen de: MX2026005362A
The present invention relates to a device for storing and loading inputs necessary for the injection of a medicament among others insulin and is a functional and ergonomic redesign of an insulin injection pen, specifically directed to older adult persons suffering from diabetes or another disease requiring the application of a medicament and presenting articular conditions such as arthritis. This design arises in response to physical limitations facing this group of users by using conventional devices, especially as regards the placement of the needle, the application of force and the precision in handling. The proposal incorporates an assisted mechanism that facilitates insertion of the needle without requiring complex movements, thereby guaranteeing greater comfort, safety and autonomy for the user. In addition, the device has an integrated cooling system that keeps the insulin at a suitable temperature, ensuring the preservation of the drug under optimal conditions. Also included is an automated injection mechanism that allows administering the dose with only pressing a side button of good size, especially designed for hands with reduced mobility. This design seeks not only to improve the use experience, but also contribute significantly to the comfortable and easy handling for people with muscular mobility limitations such as arthritis.
Nº publicación: WO2026206121A1 01/10/2026
Solicitante:
HME SQUARE INC [KR]
(\uC8FC)\uC5D0\uC774\uCE58\uC5E0\uC774\uC2A4\uD018\uC5B4
Resumen de: WO2026206121A1
A photoacoustic measurement device of the present invention comprises a first housing and a second housing. The first housing accommodates a light source. The second housing accommodates an ultrasonic sensor and is in acoustic contact with the first housing. The characteristic acoustic impedance of a first material constituting the first housing is greater than the characteristic acoustic impedance of a second material constituting the second housing. The first housing further includes an opening through which light generated by the light source is emitted. The second housing further includes an optical path through which the light generated by the light source is guided. The optical path of the second housing is formed in a direction in which the light travels from the opening of the first housing.
BOPI
Sede Electrónica
